Close Menu

Almac

Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.

The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.

The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.

Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.

The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.

The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment. 

A brief recap of Genetics/Genomics news the week of Oct 7, 2016: SEC, Exact Sciences, Eurofins MWG Operon, Almac Group, California Blood organizations, Stat-Diagnostica, and Biofortuna

The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.

The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.